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OBJECTIVEdParticipants in ADVANCE were drawn from many countries. We examined
whether the effects of intensive glycemic control onmajor outcomes in ADVANCEdiffer between
participants from Asia, established market economies (EMEs), and eastern Europe.
RESEARCH DESIGN AND METHODSdADVANCE was a clinical trial of 11,140
patients with type 2 diabetes, lasting a median of 5 years. Demographic and clinical character-
istics were compared across regions using generalized linear and mixed models. Effects on out-
comes of the gliclazide modiﬁed release–based intensive glucose control regimen, targeting an
HbAlc of #6.5%, were compared across regions using Cox proportional hazards models.
RESULTSdWhen differences in baseline variables were allowed for, the risks of primary out-
comes (major macrovascular or microvascular disease) were highest in Asia (joint hazard ratio
1.33 [95% CI 1.17–1.50]), whereas macrovascular disease was more common (1.19 [1.00–
1.42]) and microvascular disease less common (0.77 [0.62–0.94]) in eastern Europe than in
EMEs. Risks of death and cardiovascular death were highest in eastern Europe, and the mean
difference in glycosylated hemoglobin between the intensive and standard groups was lowest in
EMEs. Despite these and other differences, the effects of intensive glycemic control were not
signiﬁcantly different (P$ 0.23) between regions for any outcome, including mortality, vascular
end points, and severe hypoglycemic episodes.
CONCLUSIONSdIrrespective of absolute risk, the effects of intensive glycemic control with the
gliclazideMR-based regimen used in ADVANCEwere similar across Asia, EMEs, and eastern Europe.
This regimen can safely be recommended for patients with type 2 diabetes in all of these regions.
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E stimates and projections of the globalburden of diabetes clearly show thatthis burden is widely dispersed and
that diabetes is by no means merely a
problem of established market economies
(EMEs) (1). Indeed, none of the top ten
countries by diabetes prevalence in the
latest International Diabetes Federation
statistics are EMEs (2). Furthermore, in
all parts of the world the prevalence of
diabetes is expected to rise over the next
20 years (1,2). This argues for a global
approach to prevention of the undesirable
consequences of diabetes, the most im-
portant of which are macrovascular and
microvascular disease.
Guidelines for treatment of patients
with diabetes across the world stress the
importance of glycemic control, although
the target levels and ﬁrst-line drugs of
choice vary (3). Whether these variations
reﬂect real differences in the effects of glyce-
mic control across regions is unknown. The
ADVANCE (Action in Diabetes and Vascu-
lar Disease: Preterax and Diamicron Modi-
ﬁed Release (MR) Controlled Evaluation)
trial (4) had the broadest worldwide cov-
erage of patients of any trial of diabetes yet
conducted, although relatively few partic-
ipants (4%) came from North America.
In general, ADVANCE found favorable,
but nonsigniﬁcant, effects of an intensive
glycemic control regimen, compared with
local standard control regimens, on cardio-
vascular events and all-cause mortality and
beneﬁcial effects on microvascular compli-
cations. The objective of this study was
to determinewhether these generally favor-
able effects of glycemic control were
consistent across the ADVANCE trial pop-
ulations recruited from Asia, EMEs, and
eastern Europe.
RESEARCH DESIGN AND
METHODSdADVANCE was a double-
blind factorial randomized controlled trial
conducted by 215 collaborating centers
in 20 countries, involving 11,140 patients
(lists of participating centers and personnel
can be found in the Supplementary Ap-
pendix). Detailed study methods have
previously been published (4,5). In brief,
subjects had type 2 diabetes diagnosed at
$30 years of age, were$55 years of age at
entry to the study, and had either existing
cardiovascular disease or at least one risk
factor for that disease. Patients were ineli-
gible if they had a deﬁnite indication for,
or contraindication to, either of the active
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study treatments or had a deﬁnite indica-
tion for long-term insulin therapy. Sub-
jects were randomized to 1) the ﬁxed
combination of the ACE inhibitor, peri-
ndopril, and the diuretic, indapamide
(2 mg/0.625 mg, doubled to 4 mg/1.25
mg after 3 months) or matching placebos
and 2) intensive (gliclazide MR based, to
an HbA1c target of #6.5%) or standard
(usual care) glucose control. Patients were
followed up for a median of 5.0 years.
The two primary study outcomes were
as follows: macrovascular events (cardio-
vascular death, nonfatal myocardial infarc-
tion, or nonfatal stroke) and microvascular
events (new or worsening nephropathy
or retinopathy), analyzed separately and
jointly. Prespeciﬁed secondary outcomes
were total deaths, cardiovascular disease
deaths, major coronary events (death due
to coronary heart disease, including sud-
den death, and nonfatal myocardial in-
farction), total coronary events (major
coronary events, silent myocardial in-
farction, coronary revascularization, or hos-
pital admission for unstable angina), major
cerebrovascular events (death due to cere-
brovascular disease or nonfatal stroke), total
cerebrovascular events (major cerebrovas-
cular events, transient ischemic attack, or
subarachnoid hemorrhage), new or wors-
ening nephropathy (development of new
macroalbuminuria, doubling of serum cre-
atinine to a level of at least 200 mmol/L,
need for renal replacement therapy, or
death due to renal disease), development of
new microalbuminuria, total renal events
(new or worsening nephropathy or new
microalbuminuria), new or worsening
retinopathy, visual deterioration, and
total retinopathy (development of pro-
liferative retinopathy, macular edema,
or diabetes-related blindness or retinal
photocoagulation therapy). An indepen-
dent Endpoint Adjudication Committee,
blinded to treatment allocation, re-
viewed source documentation for all in-
dividuals who had a suspected primary
end point or who died during follow-up.
Statistical methods
The 20 countries involved in ADVANCE
were divided according to standard def-
initions (1) into three groups, listed with
number of patients per country in paren-
theses: Asia (n = 4,136), comprising
China (n = 3,293), India (n = 471), Malay-
sia (n = 236), and the Philippines (n =136);
EMEs (n = 4,862), comprising Australia
(n = 978), Canada (n = 436), France (n =
196), Germany (n = 327), Ireland (n = 442),
Italy (n = 21), the Netherlands (n = 507),
New Zealand (n = 630), and the U.K.
(n = 1,325); and eastern Europe (n =
2,142), comprising the Czech Republic
(n = 209), Estonia (n = 155), Hungary
(n = 434), Lithuania (n = 118), Poland
(n = 604), Russia (n = 164), and Slovakia
(n = 458).
Baseline demographic and clinical data,
including methods of glycemic control,
were compared between the three regions,
unadjusted and after adjustment for
age, sex, and duration of diabetes, using
generalized linear models. Skewed con-
tinuous variables were transformed to
approximate normality using logarithmic
transformations. Event rates during the
trial were compared between the regions
using Cox proportional hazards regres-
sion, adjusting for a range of potential
confounding variables, taking EMEs as the
reference group.
Mean differences in HbA1c between the
intensive and the standard glycemic control
regimens during the trial were estimated for
each region using linear mixed models. The
efﬁcacy of more versus less glycemic control
was estimated for each region and reported
as the relative risk reduction for each of the
primary and secondary outcomes. This was
calculated from the hazard ratio obtained
from an unadjusted Cox proportional haz-
ards regressionmodel applied to the region-
speciﬁc data for each outcome. The number
and percentage of people suffering a severe
hypoglycemic episode were also computed
and analyzed using a logistic regression
model. In each analysis, the regions were
compared by adding a region by treatment
interaction term to the relevant statistical
model. All tests were considered signiﬁcant
if P, 0.05.
Although this study is concerned
with comparisons of regions of domicile,
issues of ethnicity are clearly related.
Hence, in secondary analyses, baseline
differences and treatment effects were also
analyzed by self-reported ethnicity.
RESULTS
Comparisons between regions at
baseline
At baseline, there were signiﬁcant (P #
0.02) differences in all the demographic
and clinical variables considered a priori
except history of microvascular disease
(Table 1). On average, people in EMEs
were the oldest, most often male, and
had the shortest lead time since diabetes
was diagnosed prior to recruitment. Sul-
phonylureas were the most common type
of glucose-lowering therapy in all regions
but were most commonly used in Asia
(Table 2). Metformin was least likely to
be taken in eastern Europe. Statins were
far more commonly used in EMEs than in
eastern Europe, which itself had a far
higher prevalence of statin use than
Asia. More patients in eastern Europe
were taking blood pressure medications
than in the other two regions. With the
exception of nonaspirin antiplatelet
agents and nonstatin lipid modiﬁers, for
which numbers were small, in unadjusted
analyses medication use was always sig-
niﬁcantly different between regions (P #
0.05). Adjustment for age, sex, and dura-
tion of diabetes made little difference, ex-
cept that insulin use then became
marginally nonsigniﬁcant (P = 0.06) (Ta-
ble 2). At the end of trial follow-up, medi-
cation use remained different across
regions (Supplementary Table 1).
Comparisons between regions over
follow-up
After differences in demographics and
baseline clinical variables, including
blood pressure and medication use,
were allowed for, there were highly sig-
niﬁcant (P # 0.001) differences in event
rates during follow-up for all outcomes
when all three regions were compared
against each other (Table 3). The risks of
macrovascular andmicrovascular disease,
analyzed jointly and separately, were
highest in Asia. In eastern Europe, macro-
vascular disease was signiﬁcantly (P #
0.05) more common but microvascular
disease signiﬁcantly less common than
in EMEs. The risk of death during the
study, including cardiovascular death,
was highest in eastern Europe. Coronary
events were signiﬁcantly more likely to oc-
cur in EMEs than in Asia or eastern Europe
but major cerebrovascular events were
signiﬁcantly less likely to occur in
EMEs. Total renal events and newmicro-
albuminuria were signiﬁcantly less likely
in EMEs than in Asia or eastern Europe.
The risk of eye events differed signiﬁcantly
between EMEs and each of the other re-
gions, being highest in Asia and lowest in
eastern Europe. Similar differences were
found when unadjusted analyses were
made.
The mean (95% CI) differences in
HbA1c during the trial, intensive minus
standard control, were 20.78% (20.83
to 20.74) for Asia, 20.55% (20.59 to
20.50) for EMEs, and 20.71% (20.78
to 20.64) for eastern Europe (P ,
0.0001). Adjustment for age, sex, and du-
ration of diabetes did not change any of
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these estimates or CIs by .0.01. The ef-
fects of intensive glycemic control tended
to be greater in Asia than elsewhere for
both macro- and microvascular events
(Fig. 1), although any differences are ex-
plainable by chance (P$ 0.23). Therewas
also no evidence of any differences in the
relative number of people (intensive vs.
standard) suffering a severe hypoglycemic
event between the regions (P = 0.66). In
Asia, 30 (1.5%) in the standard group and
64 (3.1%) in the intensive group had a
severe hypoglycemic event; correspond-
ing numbers in EMEs were 42 (1.7%)
and 74 (3.0%) and in eastern Europe
were 9 (0.8%) and 16 (1.2%).
Ethnicity
Of participants in Asia, 99.7% reported
themselves to be of Asian ethnicity while
99.8% of those in eastern Europe and
Table 1dBaseline characteristics in the ADVANCE population by region
Asia EME Eastern Europe P
n 4,136 4,862 2,142
Age (years) 64.5 6 5.7 67.1 6 6.4 65.3 6 6.9 ,0.0001
Women 1,926 (46.6) 1,614 (33.2) 1,193 (55.7) ,0.0001
Age diabetes ﬁrst diagnosed (years) 56.1 6 8.3 59.6 6 8.8 57.1 6 8.6 ,0.0001
Duration of diabetes (years) 8 (3–12) 6 (3–11) 7 (3–12) ,0.0001
History of macrovascular disease 1,261 (30.5) 1,558 (32.0) 771 (36.0) ,0.0001
Myocardial infarction 264 (6.4) 734 (15.1) 336 (15.7) ,0.0001
Stroke 576 (13.9) 275 (5.7) 172 (8.0) ,0.0001
Other 3,335 (80.6) 3,910 (80.4) 1,666 (77.8) 0.02
History of microvascular disease 496 (12.0) 461 (9.5) 198 (9.2) 0.44
Macroalbuminuria 178 (4.3) 151 (3.1) 75 (3.5) 0.80
Microalbuminuria 1,272 (31.5) 1,079 (23.6) 506 (25.0) 0.19
Eye disease 340 (8.2) 327 (6.7) 128 (6.0) 0.08
Current smoking 561 (13.6) 627 (12.9) 362 (16.9) ,0.0001
BMI (kg/m2) 25.3 6 3.4 30.0 6 5.3 30.6 6 5.0 ,0.0001
Waist circumference (cm) 90.1 6 9.4 103.6 6 12.7 103.4 6 11.8 ,0.0001
Fasting blood glucose (mmol/L) 8.55 6 3.00 8.32 6 2.50 8.76 6 2.88 ,0.0001
Nonstandardized HbA1c (%) 7.75 6 1.76 7.28 6 1.22 7.60 6 1.73 ,0.0001
Standardized HbA1c (%)* 7.72 6 1.87 7.26 6 1.30 7.52 6 1.78 ,0.0001
Systolic blood pressure (mmHg) 141.1 6 21.7 146.1 6 20.7 150.0 6 21.7 ,0.0001
Diastolic blood pressure (mmHg) 78.8 6 10.9 80.5 6 10.4 84.5 6 11.1 ,0.0001
Serum LDL cholesterol (mmol/L) 3.18 6 1.01 2.90 6 1.00 3.50 6 1.05 ,0.0001
Serum HDL cholesterol (mmol/L) 1.29 6 0.37 1.22 6 0.34 1.26 6 0.33 ,0.0001
Serum triglycerides (mmol/L) 1.60 (1.10–2.30) 1.62 (1.20–2.30) 1.77 (1.27–2.50) ,0.0001
Serum creatinine (mmol/L) 80 (66–96) 86 (74–100) 85 (74–98) ,0.0001
Urinary albumin-to-creatinine ratio 18.0 (8.8–49.0) 13.3 (6.2–32.7) 12.6 (5.3–34.9) ,0.0001
Data are means 6 SD, n (%), or quartile 2 (quartile 1–quartile 3) unless otherwise indicated. Triglycerides, HbA1c, creatinine, and albumin-to-creatinine ratio were
tested after transforming to approximate normality. The P value is for a test of equality between the regions after adjustment for age, sex, and duration of diabetes.
*Standardized by analyses on common standard samples (5). (All other results quoted in this article are unstandardized.)
Table 2dDrugs being taken at recruitment by region
Asia EME Eastern Europe P*
n 4,136 4,862 2,142
$1 oral glucose–lowering drugs 3,926 (94.9) 4,280 (88.0) 1,922 (89.8) ,0.0001
Gliclazide 159 (3.8) 290 (6.0) 416 (19.4) ,0.0001
Sulphonylureas 3,048 (73.7) 2,828 (58.2) 1,215 (56.7) ,0.0001
Metformin 2,639 (63.8) 3,106 (63.9) 1,007 (47.0) ,0.0001
Thiazolidinedione 98 (2.4) 300 (6.2) 9 (0.4) ,0.0001
Arcabose 595 (14.4) 201 (4.1) 164 (7.7) ,0.0001
Glinide 40 (1.0) 120 (2.5) 27 (1.3) ,0.0001
Insulin therapy 66 (1.6) 50 (1.0) 43 (2.0) 0.06
No glucose-lowering drugs 191 (4.6) 579 (11.9) 218 (10.2) ,0.0001
Aspirin 1,734 (41.9) 2,220 (45.7) 941 (43.9) 0.03
Other antiplatelet agents 168 (4.1) 236 (4.9) 102 (4.8) 0.40
Statins 458 (11.1) 2,170 (44.6) 518 (24.2) ,0.0001
Other lipid-modifying drugs 370 (8.9) 376 (7.7) 190 (8.9) 0.07
Any blood pressure–lowering drugs 2,812 (68.0) 3,617 (74.4) 1,936 (90.4) ,0.0001
Data are n (%) unless otherwise indicated. *Adjusted for age, sex, and duration of diabetes.
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93.4% of those in EMEs reported them-
selves to be of “Caucasian/European”
ethnicity (Supplementary Table 2). Con-
sequently, results were virtually the same
for Asians as for residents of Asia and re-
sults for Caucasian/Europeans were
essentially a weighted average of those
for eastern Europe and EMEs in the
regional analyses (Supplementary Tables
3 and 4).
CONCLUSIONSdADVANCE was a
global study of patients with diabetes at
moderate to high risk of future vascular
disease. Subjects in ADVANCE differed
signiﬁcantly between geographical regions
in age, sex, and other baseline character-
istics, as well as in the medications taken.
There were also important differences
between the regions in the rates at which
major clinical outcomes occurred during
the trial. The risk of coronary events was
higher, but the risk of cerebrovascular
events lower, in EMEs than in the other
regions. Adverse renal and ocular micro-
vascular events were more likely in Asia
than in EMEs. Eastern European patients
were more likely than their EME counter-
parts to experience new albuminuria and
signiﬁcantly less likely to report an eye
event. Eastern Europeans had by far the
highest rates of death. These event rates
differed even after accounting for differ-
ences in baseline clinical characteristics
and medication use across the regions.
Intensive treatment, as expected, con-
trolled HbA1c better than standard care in
all regions, but there was a small but sig-
niﬁcant difference between the regions,
such that intensive care had less effect in
EMEs than elsewhere. To some extent,
this was due to the differential levels of
HbA1c across regions at baseline. The rel-
atively smaller reduction in glycated he-
moglobin probably contributed to the
lower risk reduction seen for the effect
of randomized treatment on the compos-
ite primary outcome in EMEs (4% relative
risk reduction) versus both eastern
Europe (16%) and Asia (10%). Despite
this, there were no signiﬁcant differences
between regions in the effect of intensive
treatment for any of the hard outcomes
analyzed.
As far as we are aware, this is the ﬁrst
comparison of international regional ef-
fects within a randomized clinical trial of
glycemic control. The strengths of our study
are the large numbers, wide geographi-
cal coverage, and standardized procedures.
Even so, we do not have the numbers to
produce reliable estimates for individual
countries or any subjects from the Americas
south of Canada or from Africa.
In conclusion, we have shown that
the beneﬁts of intensive glycemic control
on vascular disease and the lack of harm
in relation to mortality, which were mani-
fest with the gliclazide MR-based regimen
in ADVANCE overall, are shared between
the three major regions from which sub-
jects were recruited. This is so despite
differences in health care systems, clinical
practice, and use of medications (includ-
ing statins and blood pressure–lowering
medication). The methods of glycemic
control used in ADVANCE can thus be
safely recommended for Caucasian and
Table 3dHazard ratios for end points comparing regions (EMEs: base)
Hazard ratio (95% CI) P*
Combined macro- plus microvascular disease
Asia 1.33 (1.17–1.50) ,0.001
Eastern Europe 1.01 (0.88–1.16) 0.87
Macrovascular disease
Asia 1.31 (1.11–1.56) 0.002
Eastern Europe 1.19 (1.00–1.42) 0.05
Microvascular disease
Asia 1.36 (1.15–1.60) ,0.001
Eastern Europe 0.77 (0.62–0.94) 0.01
All deaths
Asia 1.08 (0.90–1.30) 0.38
Eastern Europe 1.43 (1.20–1.71) ,0.001
Cardiovascular death
Asia 1.19 (0.92–1.54) 0.18
Eastern Europe 1.64 (1.29–2.09) ,0.001
Total coronary events
Asia 0.72 (0.60–0.85) ,0.001
Eastern Europe 0.79 (0.67–0.95) 0.01
Major coronary events
Asia 0.84 (0.66–1.05) 0.13
Eastern Europe 1.11 (0.88–1.38) 0.38
Total cerebrovascular events
Asia 2.02 (1.62–2.51) ,0.001
Eastern Europe 1.23 (0.96–1.57) 0.10
Major cerebrovascular events
Asia 2.40 (1.84–3.14) ,0.001
Eastern Europe 1.52 (1.14–2.03) 0.005
Total renal events
Asia 1.73 (1.57–1.91) ,0.001
Eastern Europe 1.29 (1.16–1.43) ,0.001
New or worsening nephropathy
Asia 1.42 (1.11–1.82) 0.005
Eastern Europe 0.80 (0.60–1.08) 0.15
New microalbuminuria
Asia 1.97 (1.77–2.19) ,0.001
Eastern Europe 1.36 (1.21–1.53) ,0.001
Total eye events
Asia 1.21 (1.13–1.30) ,0.001
Eastern Europe 0.72 (0.66–0.79) ,0.001
New or worsening retinopathy
Asia 1.35 (1.09–1.67) 0.006
Eastern Europe 0.74 (0.56–0.97) 0.03
Visual deterioration
Asia 1.22 (1.14–1.31) ,0.001
Eastern Europe 0.72 (0.66–0.79) ,0.001
Hazard ratios adjusted for age, sex, duration of diabetes, histories of macrovascular and microvascular disease,
current smoking, waist circumference, systolic and diastolic blood pressure, total and HDL cholesterol, trigly-
cerides, HbA1c, creatinine, albumin-to-creatinine ratio, any oral hypoglycemic drug, aspirin plus other antiplatelet
agents, statins plus other lipid-modifying drugs, any blood pressure–lowering drug, and randomized treatment
allocations (n = 11,140). *Comparison with EMEs. (All three-way comparisons have P , 0.001.)
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Asian patients with type 2 diabetes in all
three regions studied who are at moder-
ate to high risk of cardiovascular disease.
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